trialsTrialPositive

lidERA

The first oral SERD to reduce recurrence after surgery, by about 30%, compared with today's hormone pills.

Presented SABCS December 2025: ~30% reduction in invasive disease-free survival events versus standard endocrine therapy, consistent across menopausal status (ASCO 2026 subgroup: 35% pre-, 26% post-menopausal). Regulatory submission planned. If approved, the first change to adjuvant endocrine backbone since aromatase inhibitors.

Setting

Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years

Phase

Phase 3

Sponsor

Roche / Genentech

Registry

Headline result

iDFS ~30% relative reduction (HR ~0.70).

Started

2021-08-27

Reported

2025

Enrolled

4,170 enrolled

Replication

Awaits CAMBRIA-1/-2 (camizestrant) and EMBER-4 (imlunestrant) adjuvant readouts.

Outcomes

In plain words

What these results mean for people, not percentages

4,170 enrolled

Invasive disease-free survivalprimarysurrogate endpoint

The treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7).
The absolute difference, how many more people out of 100 were helped, is not reported here.
30% reduction in iDFS events vs standard ET

This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
These results apply to the people the trial enrolled: Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years. People in a different situation may not see the same effect.
The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

4,170 enrolled.

Invasive disease-free survivalprimary

HR 0.7

30% reduction in iDFS events vs standard ET

Endpoint	Arm	n	Value	HR (95% CI)	p	Source
Invasive disease-free survivalprimary	Giredestrant	-	30% reduction in iDFS events vs standard ET	0.7	-	link
Invasive disease-free survivalprimary	Standard endocrine therapy	-	-	0.7	-	link

Replication

Awaits CAMBRIA-1/-2 (camizestrant) and EMBER-4 (imlunestrant) adjuvant readouts.

Connected

Similar pages

cancers

High-risk early HR-positive breast cancer HR-positive / HER2-negative breast cancer

technologies

Endocrine therapy (SERMs, AIs, SERDs)

targets

Estrogen receptor (ERα)

drugs

Phase 3Oral SERD

companies

Roche / Genentech

roadmaps

Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test